Biopharma Bonanza

Several hedge funds saw their investments more than quadruple in the month since they invested in this merger.


Illustration by II

Talk about a return on investment.

In the four weeks since two biopharma companies merged to form Korro Bio, the new stock has more than quadrupled. And a slew of high-profile hedge funds are among the biggest beneficiaries.

On November 3, Korro Bio merged with Frequency Therapeutics and now operates under the name Korro Bio.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.